Iovance Biotherapeutics Inc
(HAM:2LB)
€
3.775
+0.090 (+2.44%)
Market Cap: 1.64 Bil
Enterprise Value: 1.41 Bil
PE Ratio: 0
PB Ratio: 2.54
GF Score: 44/100 Iovance Biotherapeutics Inc at BTIG Virtual Biotechnology Conference Transcript
Aug 11, 2020 / 06:30PM GMT
Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst
Great. Thank you, Sara. So, exciting time.
Questions & Answers
Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst
Wanted to know a little bit about your thoughts on uptake. How complex is the actual TIL delivery process? Do you have a sense of which hospitals can handle this? Are they the same CAR-T hospitals? Do you have the same sort of expected side effects? Just your thoughts around the original uptake, who's going to be comfortable in the early stages?
Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations
Sure. So we are partnering now with the leading U.S. cancer centers to prepare for the launch of lifileucel. We are targeting about 40 clinical sites at launch. A lot of these sites have had experience directly with TIL as part of our clinical studies.
And as you mentioned, because CAR-T is also a more complex process that has certainly done a good job
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot